GDF2 and pulmonary arterial hypertension: Even if these conflicting aspects of BMP9 function were to be resolved in favor of a beneficial role in PAH, the clinical value of this approach would depend on development of BMP9 agonists with extended circulating half-lives to avoid impractical dosing regimens in patients.